首页 > 市场调查报告书 > 製药

药物开发

市场调查报告书

商品编码

1454741

体外毒理学测试市场 - 产品和服务、终点和测试、技术、方法、产业 - 全球预测，2024 年 - 2032 年

In-vitro Toxicology Testing Market - Product and Services, Endpoint and Test, Technology, Method, Industry - Global Forecast, 2024 - 2032

出版日期: 2024年02月07日 | 出版商:

Global Market Insights Inc. | 英文 270 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计从 2024 年到 2032 年，体外毒理学测试市场规模将以超过 7.7% 的CAGR增长，这主要是由于出于伦理问题和监管压力，越来越多地采用体外方法而不是动物测试。人们越来越认识到化学物质对人类健康的不利影响，以及细胞培养技术的发展，正在加速体外测试的吸引力。

近年来，药品、化妆品和化学品等各行业的药物开发和化学品风险评估过程中的安全性评估越来越受到重视。毒理学研究资金的可用性和高通量筛选分析的开发将进一步提高体外毒理学测试解决方案的使用率。例如，2023 年 8 月，Altis Biosystems 推出了 RepliGut(R) Planar InflammaScreen(TM) 服务，利用人源体外结肠发炎模型来增强发炎性肠道疾病 (IBD) 的药物发现。

体外毒理学测试产业分为产品和服务、终点和测试、技术、方法、产业和地区。

在产品和服务方面，由于对高通量筛选分析的需求不断增加，从2024年到2032年，分析领域的市场规模将以8%的成长率成长。检测技术的不断进步使得结果更加准确可靠。人们越来越关注开发针对特定毒理学终点的专门测定方法，这将增加体外测试的渗透率。针对不同应用客製化的各种检测试剂盒和服务的可用性也将推动该细分市场的成长。

在终点和测试方面，预计从 2024 年到 2032 年，基因毒性领域的体外毒理学测试行业将以 8% 的CAGR增长。这是由于基因毒性测试方法的进步、各个领域对基因毒性化合物的监管审查力度加大。行业，以及人们对与遗传毒性物质相关的潜在危害的认识不断增强。用于评估遗传毒性的新测定方法和测试策略的开发也将增加对遗传毒性测试中体外测试的需求。

从地区来看，亚太地区体外毒理学测试市场在预计时间内将呈现 8.2% 的成长率。这可以归因于工业化程度的不断提高、人们对毒性测试在药物开发和化学品安全评估中的重要性的认识不断提高，以及严格的产品安全监管指南。製药和生物技术领域不断增长的研发活动以及不断扩大的医疗基础设施将刺激该地区体外毒理学测试解决方案的采用。

产业生态系统分析
产业影响力
- 成长动力
  - 政府对毒理学研究的资助增加
  - 增加研发投入
  - 技术进步
  - 对动物实验的抵制日益增加
- 产业陷阱与挑战
  - 严格的监管限制
  - 缺乏研究复杂终点的体外模型
成长潜力分析
技术景观
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品和服务划分，2018 年 - 2032 年

主要趋势
耗材
化验
- 细菌毒性测定
- 酶毒性测定
- 基于细胞的 ELISA 和蛋白质印迹
- 受体结合测定
- 组织培养测定
- 其他检测
装置
软体
服务

第 6 章：市场估计与预测：按端点和测试，2018 年 - 2032 年

主要趋势
吸收、分布、代谢和排泄 (ADME)
皮肤刺激、腐蚀、致敏
遗传毒性
细胞毒性
眼部毒性
器官毒性
光毒性
皮肤毒性
其他终点和测试

第 7 章：市场估计与预测：按技术划分，2018 年 - 2032 年

主要趋势
细胞培养
高通量
毒理基因组学

第 8 章：市场估计与预测：依方法，2018 - 2032

主要趋势
细胞检测
生化检测
电脑模型
离体模型

第 9 章：市场估计与预测：按产业划分，2018 年 - 2032 年

主要趋势
药品和生物製药
化妆品及家居用品
食物
化学品

第 10 章：市场估计与预测：按地区，2018 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Catalent, Inc.
Charles River Laboratories International, Inc.
Danaher Corporation
Eurofins Scientific
Evotec S.E.
Laboratory Corporation of America Holdings
Merck KGaA
Quest Diagnostics Incorporated
SGS Societe Generale de Surveillance SA
Thermo Fisher Scientific Inc.

简介目录

Product Code: 5543

In-vitro Toxicology Testing Market size is predicted to expand at over 7.7% CAGR from 2024 to 2032, mainly led by the increasing adoption of in-vitro methods over animal testing due to ethical concerns and regulatory pressures. The rising awareness about the adverse effects of chemicals on human health and the developments in cell culture technologies are accelerating the appeal of in-vitro testing.

Lately, there has been growing emphasis on safety assessment during drug development and chemical risk assessment in various industries, such as pharmaceuticals, cosmetics, and chemicals. The availability of funding for research in toxicology and the development of high-throughput screening assays will further increase the utilization of in-vitro toxicology testing solutions. For instance, in August 2023, Altis Biosystems launched RepliGut(R) Planar InflammaScreen(TM) Services to enhance drug discovery for inflammatory bowel diseases (IBD) using a human-derived in vitro model of colon inflammation.

The in-vitro toxicology testing industry is segregated into product and services, endpoint and test, technology, method, industry, and region.

With respect to product and services, the market size from the assays segment will rise at 8% growth rate from 2024 to 2032, on account of the increasing demand for high-throughput screening assays. Rising advancements in assay technologies are allowing for more accurate and reliable results. The growing focus on developing specialized assays for specific toxicological endpoints will increase the penetration of in-vitro testing. The availability of a wide range of assay kits and services tailored to different applications will also drive the segment growth.

In terms of endpoint and test, the in-vitro toxicology testing industry from the genotoxicity segment is anticipated to rise at 8% CAGR from 2024 to 2032. This is due to the advancements in genotoxicity testing methods, increased regulatory scrutiny on genotoxic compounds in various industries, and the growing awareness about the potential hazards associated with genotoxic substances. The development of novel assays and testing strategies for assessing genotoxicity will also increase the demand for in-vitro testing in genotoxicity testing.

Regionally, the Asia Pacific in-vitro toxicology testing market will depict 8.2% growth rate during the projected timeframe. This can be attributed to the increasing industrialization, rising awareness about the importance of toxicity testing in drug development and chemical safety assessment, as well as stringent regulatory guidelines for product safety. The growing R&D activities in pharmaceutical and biotechnology sectors along with the expanding healthcare infrastructure will stimulate the adoption for in-vitro toxicology testing solutions in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in government funding for toxicology research
  - 3.2.1.2 Increased R&D investments
  - 3.2.1.3 Technological advancements
  - 3.2.1.4 Growing resistance against animal testing
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory restrictions
  - 3.2.2.2 Lack of in-vitro models to study complex end-points
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Services, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Consumables
5.3 Assays
- 5.3.1 Bacterial toxicity assays
- 5.3.2 Enzyme toxicity assays
- 5.3.3 Cell-based ELISA and western blots
- 5.3.4 Receptor binding assays
- 5.3.5 Tissue culture assays
- 5.3.6 Others assays
5.4 Equipment
5.5 Software
5.6 Services

Chapter 6 Market Estimates and Forecast, By Endpoint and Test, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Absorption, distribution, metabolism, and excretion (ADME)
6.3 Skin irritation, corrosion, sensitization
6.4 Genotoxicity
6.5 Cytotoxicity
6.6 Ocular toxicity
6.7 Organ toxicity
6.8 Phototoxicity
6.9 Dermal toxicity
6.10 Other endpoints and tests

Chapter 7 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Cell culture
7.3 High throughput
7.4 Toxicogenomics

Chapter 8 Market Estimates and Forecast, By Method, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 Cellular assays
9.3 Biochemical assays
9.4 In silico models
9.5 Ex vivo models

Chapter 9 Market Estimates and Forecast, By Industry, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Pharmaceuticals and biopharmaceuticals
8.3 Cosmetics and household products
8.4 Food
8.5 Chemicals

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa